PHARMAUST LIMITED (PAA)
Share Price Analysis and Chart
Enter the company code or Name for stock analysis:
PAA - PHARMAUST LIMITED
FNArena Sector :
NONE
Year End: June
GICS Industry Group : NONE
Debt/EBITDA: N/A
Index:
FNArena Sector : NONE
Year End: June
GICS Industry Group : NONE
Debt/EBITDA: N/A
| LAST PRICE | CHANGE +/- | CHANGE % | VOLUME |
|---|---|---|---|
|
$0.29
22 Apr |
OPEN $0.29 |
HIGH $0.31 |
768,304 LOW $0.29 |
0.005FNARENA'S MARKET CONSENSUS FORECASTS
- No Record -
HISTORICAL DATA ARE ALL IN AUD
Copyright © 2024 FactSet UK Limited. All rights reserved
| Title | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|---|
| EPS Basic | xxx | xxx | xxx | xxx | xxx | -1.9 |
| DPS All | xxx | xxx | xxx | xxx | xxx | 0.0 |
| Sales/Revenue | xxx | xxx | xxx | xxx | xxx | 2.8 M |
| Book Value Per Share | xxx | xxx | xxx | xxx | xxx | 1.1 |
| Net Operating Cash Flow | xxx | xxx | xxx | xxx | xxx | -1.6 M |
| Net Profit Margin | xxx | xxx | xxx | xxx | xxx | -219.96 % |
EPS Basic
DPS All
Sales/Revenue
Book Value Per Share
Net Operating Cash Flow
Net Profit Margin
| Title | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|---|
| Return on Capital Employed | xxx | xxx | xxx | xxx | xxx | -105.88 % |
| Return on Invested Capital | xxx | xxx | xxx | xxx | xxx | -90.94 % |
| Return on Assets | xxx | xxx | xxx | xxx | xxx | -76.65 % |
| Return on Equity | xxx | xxx | xxx | xxx | xxx | -105.88 % |
| Return on Total Capital | xxx | xxx | xxx | xxx | xxx | -51.14 % |
| Free Cash Flow ex dividends | xxx | xxx | xxx | xxx | xxx | -1.6 M |
Return on Capital Employed
Return on Invested Capital
Return on Assets
Return on Equity
Return on Total Capital
Free Cash Flow ex dividends
| Title | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|---|
| Short-Term Debt | xxx | xxx | xxx | xxx | xxx | 0 M |
| Long Term Debt | xxx | xxx | xxx | xxx | xxx | 1 M |
| Total Debt | xxx | xxx | xxx | xxx | xxx | 1 M |
| Goodwill - Gross | xxx | xxx | xxx | xxx | xxx | - |
| Cash & Equivalents - Generic | xxx | xxx | xxx | xxx | xxx | 3 M |
| Price To Book Value | xxx | xxx | xxx | xxx | xxx | 6.70 |
Short-Term Debt
Long Term Debt
Total Debt
Goodwill - Gross
Cash & Equivalents - Generic
Price To Book Value
| Title | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|---|
| Capex | xxx | xxx | xxx | xxx | xxx | 0.0 M |
| Capex % of Sales | xxx | xxx | xxx | xxx | xxx | 1.24 % |
| Cost of Goods Sold | xxx | xxx | xxx | xxx | xxx | 4 M |
| Selling, General & Admin. Exp & Other | xxx | xxx | xxx | xxx | xxx | 3 M |
| Research & Development | xxx | xxx | xxx | xxx | xxx | 1 M |
| Investments - Total | xxx | xxx | xxx | xxx | xxx | - |
Capex
Capex % of Sales
Cost of Goods Sold
Selling, General & Admin. Exp & Other
Research & Development
Investments - Total
EXPERT VIEWS
Display All Commentary
Sentiment Indicator
0.0
No. Of Recommendations
0
PAA STOCK CHART
FNArena News on PAA
| 1 |
Race Oncology Booming Ahead In Times Of CovidAug 28 2020 - Small Caps |
| 2 |
Rudi’s View: Osteopore, Whitehaven Coal and TelstraDec 06 2019 - Rudi's View |